To analyze the expression of vascular endothelial growth factor A (VEGF- A) and receptors (VEGFR- 1 and VEGFR- 2) in endometrial blood vessels, as well as microvascular density (MVD), in endometrial biopsy samples fro...To analyze the expression of vascular endothelial growth factor A (VEGF- A) and receptors (VEGFR- 1 and VEGFR- 2) in endometrial blood vessels, as well as microvascular density (MVD), in endometrial biopsy samples from idiopathic menorrhagia patients. Design: Prospective clinical study. Setting: University hospital, unit of gynecology. Patient(s): Twenty-four patients with idiopathic menorrhagia and 18 healthy fertile women. Intervention(s): Blood sampling for hormone measurement, hysteroscopy, and endometrial biopsy sampling. Endometrial biopsy samples were used for immunohistochemistry assessments and image analysis of stained endothelial structures for VEGF- A, VEGFR- 1, VEGFR- 2, and CD34. Main Outcome Measure(s): Appearance of the endometrial vascular immunoreactivity for VEGF- A, VEGFR- 1, and VEGFR- 2, MVD and computer-assisted stereological analysis of immunoassayed blood vessels. Result(s): Although the MVD did not differ between patients and controls, we observed that vascular expression of VEGF- A, VEGFR- 1, and VEGFR- 2 in capillaries was 1.8- fold, 1.8- fold, and 2.0- fold higher, respectively, in the menorrhagia group when assessed as the number of stained capillaries per unit area. There were also a twofold higher number of arterioles, which were VEGFR- 2 positive in the menorrhagia group. Conclusion(s): Up-regulation of VEGF- A and receptors VEGFR- 1 and VEGFR- 2 in capillaries in menorrhagia could be involved in abnormal endometrial vascular structure and permeability.展开更多
肿瘤标志物可用于肿瘤的早期发现、诊断以及疗效与预后的判断。例如标志物CEA和CA125目前已广泛用于多种实体瘤包括肺癌的疗效监测及预后判断。由于肿瘤的发生发展涉及到多基因、多步骤，一种肿瘤标志物可以在不同的肿瘤中表达，而同一...肿瘤标志物可用于肿瘤的早期发现、诊断以及疗效与预后的判断。例如标志物CEA和CA125目前已广泛用于多种实体瘤包括肺癌的疗效监测及预后判断。由于肿瘤的发生发展涉及到多基因、多步骤，一种肿瘤标志物可以在不同的肿瘤中表达，而同一肿瘤又可表达多种标志物。近年来，血管内皮生长因子（Blood vascular endothelial growth factor VEGF ）及金属硫蛋白（metallothionein M T ）的肿瘤标志物相关研究受到广泛关注。VEGF（亦即VEGF-A ，但通常简称为VEGF）是指血管内皮生长因子。VEGF对血管生长有强力诱导作用，并特异性作用于血管内皮细胞的生长因子，与肿瘤发生、发展及侵袭过程密切相关［1，2］。目前的研究表明肿瘤组织中 VEGF的表达量与肿瘤恶性程度呈正相关，其表达水平可作为区分肿瘤恶性程度及判断预后的指标［3］。肺癌患者血清V EG F高水平预示病期较晚，浸润范围广泛，病灶远处转移。因此监测晚期肺癌患者治疗前后V EG F值的变化，对晚期肺癌的疗效及预后判断具有重要价值。M T （metallothionein ，金属硫蛋白）是生物体内普遍存在的一类富含半胱氨酸、与金属离子具有高度亲和性的低分子量结合蛋白。致癌过程中MT的产生与肿瘤迅速生长、致癌物质刺激及癌基因激活有关。在许多肿瘤组织如甲状腺肿瘤、鼻咽癌、宫颈癌、乳腺癌中都发现M T 呈高水平表达［4］。本实验通过检测肺癌患者治疗前后外周血 VEGF、M T表达的情况，探索VEGF、M T 与肺癌诊治的相关性，为该标志物能否作为肺癌诊治、疗效观察、预后判断的指标提供一定的理论依据。展开更多
文摘To analyze the expression of vascular endothelial growth factor A (VEGF- A) and receptors (VEGFR- 1 and VEGFR- 2) in endometrial blood vessels, as well as microvascular density (MVD), in endometrial biopsy samples from idiopathic menorrhagia patients. Design: Prospective clinical study. Setting: University hospital, unit of gynecology. Patient(s): Twenty-four patients with idiopathic menorrhagia and 18 healthy fertile women. Intervention(s): Blood sampling for hormone measurement, hysteroscopy, and endometrial biopsy sampling. Endometrial biopsy samples were used for immunohistochemistry assessments and image analysis of stained endothelial structures for VEGF- A, VEGFR- 1, VEGFR- 2, and CD34. Main Outcome Measure(s): Appearance of the endometrial vascular immunoreactivity for VEGF- A, VEGFR- 1, and VEGFR- 2, MVD and computer-assisted stereological analysis of immunoassayed blood vessels. Result(s): Although the MVD did not differ between patients and controls, we observed that vascular expression of VEGF- A, VEGFR- 1, and VEGFR- 2 in capillaries was 1.8- fold, 1.8- fold, and 2.0- fold higher, respectively, in the menorrhagia group when assessed as the number of stained capillaries per unit area. There were also a twofold higher number of arterioles, which were VEGFR- 2 positive in the menorrhagia group. Conclusion(s): Up-regulation of VEGF- A and receptors VEGFR- 1 and VEGFR- 2 in capillaries in menorrhagia could be involved in abnormal endometrial vascular structure and permeability.
文摘肿瘤标志物可用于肿瘤的早期发现、诊断以及疗效与预后的判断。例如标志物CEA和CA125目前已广泛用于多种实体瘤包括肺癌的疗效监测及预后判断。由于肿瘤的发生发展涉及到多基因、多步骤，一种肿瘤标志物可以在不同的肿瘤中表达，而同一肿瘤又可表达多种标志物。近年来，血管内皮生长因子（Blood vascular endothelial growth factor VEGF ）及金属硫蛋白（metallothionein M T ）的肿瘤标志物相关研究受到广泛关注。VEGF（亦即VEGF-A ，但通常简称为VEGF）是指血管内皮生长因子。VEGF对血管生长有强力诱导作用，并特异性作用于血管内皮细胞的生长因子，与肿瘤发生、发展及侵袭过程密切相关［1，2］。目前的研究表明肿瘤组织中 VEGF的表达量与肿瘤恶性程度呈正相关，其表达水平可作为区分肿瘤恶性程度及判断预后的指标［3］。肺癌患者血清V EG F高水平预示病期较晚，浸润范围广泛，病灶远处转移。因此监测晚期肺癌患者治疗前后V EG F值的变化，对晚期肺癌的疗效及预后判断具有重要价值。M T （metallothionein ，金属硫蛋白）是生物体内普遍存在的一类富含半胱氨酸、与金属离子具有高度亲和性的低分子量结合蛋白。致癌过程中MT的产生与肿瘤迅速生长、致癌物质刺激及癌基因激活有关。在许多肿瘤组织如甲状腺肿瘤、鼻咽癌、宫颈癌、乳腺癌中都发现M T 呈高水平表达［4］。本实验通过检测肺癌患者治疗前后外周血 VEGF、M T表达的情况，探索VEGF、M T 与肺癌诊治的相关性，为该标志物能否作为肺癌诊治、疗效观察、预后判断的指标提供一定的理论依据。
